Welcome to our dedicated page for Entera Bio Ltd. news (Ticker: $ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entera Bio Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entera Bio Ltd.'s position in the market.
Entera Bio (NASDAQ: ENTX) has announced the appointment of Dr. Rachel B Wagman as Key Clinical Advisor and Member of its Scientific Advisory Board. Dr. Wagman brings over 20 years of experience in metabolic bone disease and women's health research, including the successful development of five molecules such as teriparatide (Forteo®), denosumab (Prolia®), and romosozumab (Evenity®). Her appointment is expected to enhance Entera's oral peptide pipeline focused on chronic metabolic disorders. CEO Miranda Toledano highlighted Dr. Wagman's patient-focused approach and therapeutic specializations. Dr. Wagman expressed her commitment to innovative treatments, particularly in osteoporosis. Her past roles include senior positions at Eli Lilly, Amgen, and Myovant Sciences.
Entera Bio (NASDAQ: ENTX) will present Phase 1 data on their investigational program EB612 at the ENDO 2024 Annual Meeting. EB612 aims to provide an oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. The study focuses on reducing daily administration frequency by using Entera's N-Tab™ technology platform.
Entera Bio reported its Q1 2024 financial results, highlighting a strong start due to its growth strategy in 2023. The company expanded its N-Tab™ therapeutic pipeline with potential first-in-class oral peptide treatments for various disorders. Entera is focused on becoming a premier oral peptide therapeutic company. Key updates include EB613 for osteoporosis, EB612 for hypoparathyroidism, and first GLP-2, GLP-1/glucagon tablets for Short Bowel Syndrome and obesity.
EB613 is the first oral PTH(1-34) daily osteoanabolic tablet for osteoporosis. EB612 is the first oral PTH(1-34) replacement therapy tablet for hypoparathyroidism. Positive in vivo PK results were announced for the oral GLP-2 tablet for Short Bowel Syndrome. Collaborative work for GLP-1/glucagon agonist tablets for obesity is ongoing. Entera also plans to use oral PTH(1-34) tablets to treat intense sport and military stress injuries.
Financially, Entera had $9.2 million in cash and cash equivalents as of March 31, 2024, with projected cash resources expected to meet operating requirements into the third quarter of 2025. Research and development expenses decreased slightly, while general and administrative expenses remained stable. The company reported a net loss of $2.0 million for the quarter.
